Seminar Title: "Can we find new treatments for a prehistoric Cancer?"
Date: 3 June 2026
ICT Seminar series
The ICT Seminar Series brings together researchers working across cancer biology, therapeutics, and clinical research. The programme features invited speakers from universities, research institutes, healthcare, and industry, covering topics that range from fundamental mechanisms of cancer progression to emerging therapeutic strategies and models.
The seminars are open to staff, students, and external visitors, aiming to support scientific discussion, collaboration, and early career development within the Institute of Cancer Therapeutics and the broader research community.
The seminars run in two parts per year. The Spring series runs between February and June and the Winter seminars runs from October to December.
For further information or if you would like to participate in the next ICT seminar series, please email S.Swaroop@bradford.ac.uk.
2026 Spring seminar series
The ICT is delighted to present the Spring seminar series 2026, a vibrant programme bringing together leading scientists, clinicians, and innovators from across the UK and beyond. Running weekly from 4 March to 03 June, this series showcases pioneering discoveries shaping the future of cancer biology, diagnostics, and therapeutics.
Each seminar offers a unique opportunity for students, researchers, and clinicians to engage with world class experts, explore emerging ideas, and strengthen collaborative networks within the cancer research community.
Across twelve weeks, the series features distinguished speakers from institutions including King’s College London, MIT, Oxford, Imperial College London, The Francis Crick Institute, CRUK Scotland Institute, and more.
Topics span molecular mechanisms of cancer progression, therapeutic innovation, tumour heterogeneity, and the evolving landscape of precision oncology.
Seminar Title: “Targeting glycans to develop new treatments for prostate cancer”
Date: 27 May 2026
Seminar Title: “From Radical Reform to Precision Systems: The Evolution of Integrated Breast Cancer Care”
Date: 20 May 2026
Seminar Title: “Targeting kinase signalling pathways in prostate cancer”
Date: 13 May 2026
Seminar Title: “New insight into the role of nuclear receptor transcription factors in cancer"
Date: 6 May 2026
Seminar Title: "The Ecosystem of Childhood Sarcoma: Microenvironmental Drivers and Therapeutic Opportunities"
Date: 29 April 2026
Seminar Title: “Rationalising the genomic and transcriptional heterogeneity in therapy-resistant breast cancer”
Date: 22 April 2026
Seminar Title: “Next generation therapeutics: targeting the invisible in ovarian cancer”
Date: 15 April 2026
Seminar Title: “The cell biology of PTEN loss-associated invasion in cancer”
Date: 8 April 2026
Seminar Title: “Impact of spatial and temporal inter‑tumoural heterogeneity in Ovarian High Grade Serous Carcinoma”
Date: 1 April 2026
Seminar Title: “Highjacked tissue regeneration as a unifying principle of cancer host interaction”
Date: 25 March 2026
Seminar Title: “Mechanisms of Malignant Progression"
Date: 18 March 2026
Seminar Title: “Taking inspiration from disease mutations to identify protein–protein interaction targets”
Date: 11 March 2026
Seminar Title: “Engineering Safer, Drug-Like Payloads for Next-Generation Antibody-Drug Conjugate”
Date: 4 March 2026
The 2025 Winter Seminar Series
The ICT Winter Seminar Series brought together researchers working across cancer biology, therapeutics, and clinical research. The programme featured invited speakers from universities, research institutes, healthcare, and industry, covering topics that range from fundamental mechanisms of cancer progression to emerging therapeutic strategies and models.
The seminars are open to all staff, students, and external visitors, aiming to support scientific discussion, collaboration, and early career development within the Institute of Cancer Therapeutics and the broader research community.
Edwin Chen is a Reader in Biomedical Science at Canterbury Christ Church University. He trained at McGill University and the University of Toronto, with postdoctoral research at the University of Cambridge and Harvard University. His work focuses on genome instability and JAK–STAT signalling in myeloid and lymphoid malignancies, with particular interest in clonal evolution.
Title: Demystifying the role of mutant calreticulin in blood cancers: ER we there yet?
Date: 1 October 2025 | 12:00–1:00 PM | Richmond E59
Professor Joanna Loizou is Senior Group Leader at the Institute of Cancer Research and Deputy Director of the Centre for Target Validation. Her research centres on DNA repair and genome stability, with a focus on identifying therapeutic vulnerabilities in cancer.
Title: Uncovering actionable vulnerabilities for the treatment of cancer
Date: 8 October 2025 | 12:00–1:00 PM | Richmond E59
Luca Magnani is Professor of Cancer Adaptation and Evolution at the Institute of Cancer Research. He leads the Breast Cancer Epigenetics and Evolution Group, focusing on chromatin regulation, tumour dormancy, and resistance in ER-positive breast cancer.
Title: Dormancy’s Dice: The Long Game of ER+ Breast Cancer
Date: 15 October 2025 | 12:00–1:00 PM | Richmond N3
Clare Hoskins is Professor of Pure and Applied Chemistry at the University of Strathclyde. Her group develops multifunctional nanoparticles and works on their translation into medical and agricultural applications.
Title: Harnessing the Potential of Nanotechnology in Cancer Theragnostics
Date: 22 October 2025 | 12:00–1:00 PM | Richmond N3
Will Brackenbury is Professor of Biomedical Sciences at the University of York and Director of the Jack Birch Cancer Research Unit. His research explores how voltage-gated sodium channels regulate breast cancer invasion and metastasis.
Title: Blocking channels to metastasis: targeting Nav1.5 in breast cancer
Date: 5 November 2025 | 12:00–1:00 PM | Richmond N3
Damir Varešlija is Senior Lecturer and Principal Investigator at Royal College of Surgeons in Ireland (RCSI), where he leads research on breast cancer brain metastasis. He is also Co-Director of the PRISM Precision Oncology Programme.
Title: Molecular Mechanisms and Therapeutic Targets of Breast Cancer Brain Metastasis
Date: 12 November 2025 | 12:00–1:00 PM | Richmond N3